U.S. Markets closed

Adverum (ADVM) Jumps: Stock Rises 5.1%

Zacks Equity Research

Adverum Biotechnologies, Inc. ADVM was a big mover last session, as the company saw its shares rise more than 5% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This continues the recent uptrend for the company—as the stock is now up 39% in the past one-month time frame.

The company has not seen any estimate revision in the past month, while the Zacks Consensus Estimate has moved lower over the same time frame, suggesting there may be trouble down the road. So, make sure to keep an eye on this stock going forward, to see if this recent move higher can last.

Adverum currently has a Zacks Rank #3 (Hold) while its Earnings ESP is negative.

Adverum Biotechnologies, Inc. Price

Adverum Biotechnologies, Inc. Price

Adverum Biotechnologies, Inc. price | Adverum Biotechnologies, Inc. Quote

Investors interested in the Medical - Biomedical and Genetics industry may consider Alnylam Pharmaceuticals, Inc. ALNY, which has a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.

Is ADVM going up? Or down? Predict to see what others think:Up or Down

More Stock News: This Is Bigger than the iPhone!

It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.

Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.

Click here for the 6 trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Alnylam Pharmaceuticals, Inc. (ALNY) : Free Stock Analysis Report
 
Adverum Biotechnologies, Inc. (ADVM) : Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research